The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
 
Karie Runcie
No Relationships to Disclose
 
Matthew Dallos
No Relationships to Disclose
 
Shaheer Khan
No Relationships to Disclose
 
Jillian Gray
No Relationships to Disclose
 
Paul Marco
No Relationships to Disclose
 
Lucie Ping
No Relationships to Disclose
 
Debra LaTourette
No Relationships to Disclose
 
Christopher B. Anderson
No Relationships to Disclose
 
Catherine S. Spina
No Relationships to Disclose
 
James B. Yu
Honoraria - Pfizer/Myovant; Reflexion Medical
 
Israel Deutsch
No Relationships to Disclose
 
Sumitra Sheeri
Employment - Advaxis
Stock and Other Ownership Interests - Advaxis
 
Andres A. Gutierrez
Employment - Advaxis
Leadership - Advaxis
Stock and Other Ownership Interests - Advaxis
Honoraria - Advaxis
 
Mark N. Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); Bellicum Pharmaceuticals; Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)